Figure 1.

Timeline of breakthrough discoveries from BCL2 identification to BCL2-based clinical therapeutics. Key milestones are indicated amongst all the discoveries achieved across this long road to the development of BCL2-based therapeutics. Many other landmark studies, such as those reporting the identification of other family members, or studies in other species that helped to characterize the mechanisms of mitochondrial apoptosis, as well as many others, are not reported owing to space constraints. FDA: Food and Drug Administration.